Erin Aho, PhD
About Erin Aho, PhD
Erin Aho, PhD, serves as the Associate Director of Biology at Exscientia in Boston, Massachusetts, where she has worked since 2022. With a strong background in oncology drug discovery and expertise in DNA damage repair, epigenetics, and chromatin biology, she has accumulated over eight years of experience in the field.
Work at Exscientia
Erin Aho serves as the Associate Director of Biology at Exscientia, a role she has held since 2022. Based in Boston, Massachusetts, she contributes to the company's focus on artificial intelligence-driven drug discovery. Her responsibilities include overseeing biological research initiatives and managing projects that align with Exscientia's mission to enhance drug development processes. Aho's expertise in oncology drug discovery supports the company's innovative approach to developing new therapeutics.
Previous Experience at Forma Therapeutics
Before joining Exscientia, Erin Aho worked at Forma Therapeutics in various capacities. She served as a Scientist, Biology from 2019 to 2021, and then as Scientist II, Biology from 2021 to 2022. Her tenure at Forma Therapeutics included a brief role as Senior Scientist I, Biology in 2022. During her time there, Aho focused on projects related to oncology, contributing to the advancement of drug discovery efforts.
Education and Expertise
Erin Aho earned her Doctor of Philosophy (PhD) in Cell and Developmental Biology from Vanderbilt University, where she studied from 2014 to 2019. Prior to her PhD, she obtained a Bachelor of Arts (BA) in Biological Sciences from the University of Delaware from 2008 to 2012. Aho possesses expertise in managing Contract Research Organizations (CROs) and academic collaborations, with a specialization in DNA damage repair, epigenetics, and chromatin biology.
Research and Academic Background
Aho has a strong academic background, having worked as a Postdoctoral Fellow at Vanderbilt University in 2019. Her research experience includes a position as a Research Technologist at Penn State University from 2012 to 2014 and as an Undergraduate Research Assistant at the University of Delaware from 2011 to 2012. Throughout her career, she has developed skills in science writing, particularly in the context of oncology drug discovery.